File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo

TitleNatural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo
Authors
KeywordsBreast cancer
Cancer recurrence
Cancer stem cells
Eriocalyxin B
Gut microbiome
Metastasis
Natural products
Issue Date2023
Citation
Biochemical Pharmacology, 2023, v. 210, article no. 115491 How to Cite?
AbstractBreast cancer is the most commonly diagnosed cancer among women, and its metastasis to distant organs accounts for the majority of death. Eriocalyxin B (Eri B), an ent-kaurane diterpenoid isolating from Isodon eriocalyx var. laxiflora, has previously been reported to have anti-tumor and anti-angiogenic effects in breast cancer. Here, we investigated the effect of Eri B on cell migration and adhesion in triple negative breast cancer (TNBC) cells, as well as aldehyde dehydrogenases 1 family member A1 (ALDH1A1) expression, colony- and sphere-formation in cancer stem cell (CSC) enriched MDA-MB-231 cells. The in vivo anti-metastatic activities of Eri B were determined in 3 different breast tumor-bearing mouse models. Our results indicated that Eri B inhibited TNBC cell migration and adhesion to extracellular matrix proteins, and also reduced ALDH1A1 expression and colony formation in CSC-enriched MDA-MB-231 cells. The metastasis-related pathways, such as epidermal growth factor receptor/ mitogen-activated protein kinase kinases 1/2/ extracellular regulated protein kinase signaling altered by Eri B was firstly shown in MDA-MB-231 cells. The potent anti-metastatic efficacies of Eri B were demonstrated in breast xenograft-bearing mice and syngeneic breast tumor-bearing mice. Gut microbiome analysis results revealed the change in the diversity and composition of microbiome after Eri B treatment, and the potential pathways that are involved in the anti-cancer efficacy of Eri B. In conclusion, Eri B was shown to inhibit breast cancer metastasis in both in vitro and in vivo models. Our findings further support the development of Eri B as an anti­metastatic agent for breast cancer.
Persistent Identifierhttp://hdl.handle.net/10722/343412
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 1.365

 

DC FieldValueLanguage
dc.contributor.authorGou, Leilei-
dc.contributor.authorYue, Grace Gar Lee-
dc.contributor.authorLee, Julia Kin Ming-
dc.contributor.authorPuno, Pema Tenzin-
dc.contributor.authorLau, Clara Bik San-
dc.date.accessioned2024-05-10T09:07:56Z-
dc.date.available2024-05-10T09:07:56Z-
dc.date.issued2023-
dc.identifier.citationBiochemical Pharmacology, 2023, v. 210, article no. 115491-
dc.identifier.issn0006-2952-
dc.identifier.urihttp://hdl.handle.net/10722/343412-
dc.description.abstractBreast cancer is the most commonly diagnosed cancer among women, and its metastasis to distant organs accounts for the majority of death. Eriocalyxin B (Eri B), an ent-kaurane diterpenoid isolating from Isodon eriocalyx var. laxiflora, has previously been reported to have anti-tumor and anti-angiogenic effects in breast cancer. Here, we investigated the effect of Eri B on cell migration and adhesion in triple negative breast cancer (TNBC) cells, as well as aldehyde dehydrogenases 1 family member A1 (ALDH1A1) expression, colony- and sphere-formation in cancer stem cell (CSC) enriched MDA-MB-231 cells. The in vivo anti-metastatic activities of Eri B were determined in 3 different breast tumor-bearing mouse models. Our results indicated that Eri B inhibited TNBC cell migration and adhesion to extracellular matrix proteins, and also reduced ALDH1A1 expression and colony formation in CSC-enriched MDA-MB-231 cells. The metastasis-related pathways, such as epidermal growth factor receptor/ mitogen-activated protein kinase kinases 1/2/ extracellular regulated protein kinase signaling altered by Eri B was firstly shown in MDA-MB-231 cells. The potent anti-metastatic efficacies of Eri B were demonstrated in breast xenograft-bearing mice and syngeneic breast tumor-bearing mice. Gut microbiome analysis results revealed the change in the diversity and composition of microbiome after Eri B treatment, and the potential pathways that are involved in the anti-cancer efficacy of Eri B. In conclusion, Eri B was shown to inhibit breast cancer metastasis in both in vitro and in vivo models. Our findings further support the development of Eri B as an anti­metastatic agent for breast cancer.-
dc.languageeng-
dc.relation.ispartofBiochemical Pharmacology-
dc.subjectBreast cancer-
dc.subjectCancer recurrence-
dc.subjectCancer stem cells-
dc.subjectEriocalyxin B-
dc.subjectGut microbiome-
dc.subjectMetastasis-
dc.subjectNatural products-
dc.titleNatural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.bcp.2023.115491-
dc.identifier.pmid36898414-
dc.identifier.scopuseid_2-s2.0-85149737859-
dc.identifier.volume210-
dc.identifier.spagearticle no. 115491-
dc.identifier.epagearticle no. 115491-
dc.identifier.eissn1873-2968-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats